{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Atossa Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"ATOS"},"Address":{"label":"Address","value":"107 SPRING STREET, SEATTLE, Washington, 98104, United States"},"Phone":{"label":"Phone","value":"+1 206 325-6068"},"Industry":{"label":"Industry","value":"Biotechnology: In Vitro &amp; In Vivo Diagnostic Substances"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in us. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use."},"CompanyUrl":{"label":"Company Url","value":"https://www.atossatherapeutics.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Bernadine Heather Fraser","title":"VP-Clinical, Regulatory &amp; CMC Division"},{"name":"Devon Payne","title":"Director-Clinical Operations"},{"name":"Richard Graydon","title":"Chief Medical Officer"},{"name":"Steven C. Quay","title":"Chairman, President &amp; Chief Executive Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}